<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081886</url>
  </required_header>
  <id_info>
    <org_study_id>PEAK VP-00082</org_study_id>
    <nct_id>NCT01081886</nct_id>
  </id_info>
  <brief_title>PEAK PlasmaBlade 4.0 Versus Traditional Electrosurgery in Total Knee Replacement.</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade 4.0 in Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Surgical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Surgical Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the operative performance of the PEAK
      PlasmaBlade 4.0 during total knee replacement; to monitor and record post-operative pain,
      activity level, narcotic consumption, adverse events, and skin scarring following surgery;
      and compare these outcomes to the current standard of care (SOC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total knee replacement is a surgical procedure performed to replace the weight-bearing
      surfaces of the knee joint. The goal of total knee replacement is to improve a patient's
      mobility by improving the function of the the knee joint.

      The PEAK PlasmaBladeÂ® uses pulsed radiofrequency (RF) energy and a highly-insulated handpiece
      design to enable precision cutting and coagulation at the point of application. The
      PlasmaBlade has received FDA clearance for use in plastic, general, orthopedic, and ear,
      nose, and throat (ENT) surgery, and has demonstrated a significantly reduced thermal injury
      profile in incised tissue compared to traditional electrosurgical devices. It is hypothesized
      that this benefit may improve the post-operative outcome of patients undergoing total knee
      replacement.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termination due to acquisition of PEAK Surgical by Medtronic
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Pain</measure>
    <time_frame>Postoperative (0 to 10 days)</time_frame>
    <description>Wong-Baker FACES Visual Analog Scale, 0 (no hurt) to 10 (hurts worst). The results represent the mean of each subject's mean pain scores over 10 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative Metrics: Operative Time, Estimated Blood Loss, Skin Scarring, Knee Society Score (KSS)</measure>
    <time_frame>Intraoperatively and 1-2 weeks postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Degenerative Joint Disease</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>PlasmaBlade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PEAK PlasmaBlade 4.0</intervention_name>
    <description>The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.</description>
    <arm_group_label>PlasmaBlade</arm_group_label>
    <other_name>Intervention</other_name>
    <other_name>PlasmaBlade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Traditional Electrosurgery with scalpel</intervention_name>
    <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Scalpel and electrosurgery</other_name>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 21 and 80 years old

          2. Physically healthy, stable weight

          3. Requiring unilateral total knee arthroplasty (TKA)

          4. Subject exhibits preoperative radiographic evidence of joint degeneration consistent
             with TKA that cannot be treated in non-operative fashion

          5. Subject has severe knee pain and disability due to degenerative joint disease

          6. Subject must understand the nature of the procedure and provide written informed
             consent prior to the procedure.

          7. Subject must be willing and able to comply with all follow-up evaluations

          8. Subject must be willing to undergo TKA using the Signature Knee System

        Exclusion Criteria:

          1. Age younger than 21 or greater than 80 years old

          2. Previous history of infection in the affected joint

          3. Peripheral vascular disease

          4. Revision procedures

          5. BMI &gt; 35

          6. Valgus or varus deformity &gt; 15 degrees

          7. Flexion contracture &gt; 15 degrees

          8. History of diabetes

          9. Anticoagulation therapy which cannot be discontinued

         10. Cognitive impairment or mental illness

         11. Severe cardiopulmonary deficiencies

         12. Known coagulopathy

         13. Immunocompromised

         14. Kidney disease (any type)

         15. Unable to follow instructions or complete follow-up

         16. Currently taking any medication known to affect healing

         17. Currently enrolled in another investigational device or drug trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DeClaire Knee and Orthopedic Institute</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Arlington Memorial Hospital</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <results_first_submitted>November 29, 2012</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 3, 2013</results_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total knee arthroplasty</keyword>
  <keyword>PlasmaBlade</keyword>
  <keyword>Electrosurgery</keyword>
  <keyword>PEAK Surgical</keyword>
  <keyword>Medtronic Advanced Energy</keyword>
  <keyword>Medtronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PlasmaBlade</title>
          <description>The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care (SOC)</title>
          <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PlasmaBlade</title>
          <description>The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care (SOC)</title>
          <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation. The protocol-specified age range is used for this baseline measure.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>21 to 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</measurement>
                    <measurement group_id="B2" value="NA">An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</measurement>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</measurement>
                    <measurement group_id="B2" value="NA">An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</measurement>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Pain</title>
        <description>Wong-Baker FACES Visual Analog Scale, 0 (no hurt) to 10 (hurts worst). The results represent the mean of each subject's mean pain scores over 10 days.</description>
        <time_frame>Postoperative (0 to 10 days)</time_frame>
        <population>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</population>
        <group_list>
          <group group_id="O1">
            <title>PlasmaBlade</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC)</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain</title>
          <description>Wong-Baker FACES Visual Analog Scale, 0 (no hurt) to 10 (hurts worst). The results represent the mean of each subject's mean pain scores over 10 days.</description>
          <population>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operative Metrics: Operative Time, Estimated Blood Loss, Skin Scarring, Knee Society Score (KSS)</title>
        <time_frame>Intraoperatively and 1-2 weeks postoperatively</time_frame>
        <population>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</population>
        <group_list>
          <group group_id="O1">
            <title>PlasmaBlade</title>
            <description>The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care (SOC)</title>
            <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
          </group>
        </group_list>
        <measure>
          <title>Operative Metrics: Operative Time, Estimated Blood Loss, Skin Scarring, Knee Society Score (KSS)</title>
          <population>An integrity audit found that the data for this study could not be analyzed owing to unverifiable source documentation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PlasmaBlade</title>
          <description>The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care (SOC)</title>
          <description>Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spider bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain/swelling</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Swain, PhD</name_or_title>
      <organization>Medtronic Surgical Technologies</organization>
      <phone>(+1-603) 294-5428</phone>
      <email>robert.e.swain@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

